• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Chiral Inversion Analysis for a Clinical-Stage Biopharmaceutical Company

Learn how Syngene enabled chiral inversion analysis through integrated in vitro and in vivo studies, delivering high-quality data that advanced drug development for a targeted protein degradation program.

Author

Latest Blogs

From Fragile to Agile: Strategic imperatives for strengthening biopharma supply chains

Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts

Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery

Paws, Pills and Progress – CRDMO’s pivotal role

Reducing variability in gene expression: Bottlenecks and Solutions

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details